中文名称 |
英文名称 |
CAS号 |
化学式 |
结构式图片 |
GW501516甲酯 |
methyl [2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]thiazol-5-yl]methyl]sulfanyl]peroxy]acetate |
317318-69-7 |
C22H20F3NO3S2 |
|
GW405833盐酸盐 |
(2,3-dichlorophenyl)(5-methoxy-2-methyl-3-(2-morpholinoethyl)-1H-indol-1-yl)methanone |
180002-83-9 |
C23H24Cl2N2O3 |
|
GSKPERK抑制剂 |
1-[5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydro-1H-indol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone |
1337531-89-1 |
C24H19F4N5O |
|
GSK789472盐酸盐 |
1-Phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride |
1257326-24-1 |
C15H22ClN3O |
|
GSK2636771甲酯 |
methyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate |
1372540-24-3 |
C23H24F3N3O3 |
|
GSK256066三氟乙酸盐 |
GSK256066 2,2,2-trifluoroacetic acid |
1415560-64-3 |
C29H27F3N4O7S |
|
GSK2334470游离态 |
GKS2334470 |
1227911-45-6 |
C25H34N8O |
|
GSK2193874游离态 |
GSK2193874 |
1336960-13-4 |
C37H38BrF3N4O |
|
GSK-3抑制剂(LY2090314) |
7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine |
603288-22-8 |
C28H25FN6O3 |
|
GSK-3beta 抑制剂 XI |
GSK-3b Inhibitor XI |
626604-39-5 |
C18H15N5O3 |
|
GSK-2110183C无结构图 |
afuresertib |
1047644-62-1 |
C18H17Cl2FN4OS |
|
GSK 525762A; (4S)-6-(4-氯苯基)-N-乙基-8-甲氧基-1-甲基-4H-[1,2,4]三唑并[4,3-a][1,4]苯并二氮杂卓-4-乙酰胺 |
I-BET762 |
1260907-17-2 |
C22H22ClN5O2 |
|
GSK 189254; 6-[(3-环丁基-2,3,4,5-四氢-1H-3-苯并氮杂卓-7-基)氧基]-N-甲基-3-吡啶甲酰胺盐酸盐 |
[3H]-GSK189254 |
945493-87-8 |
C21H25N3O2*ClH |
|
GSK 1292263 盐酸盐 |
5-[({1-[3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-2-[4-(methylsulfonyl)phenyl]pyridine hydrochloride |
1032824-54-6 |
C23H28N4O4S*ClH |
|
GSK 1059615; (5Z)-5-[[4-(4-吡啶基)-6-喹啉基]亚甲基]-2,4-噻唑烷二酮 |
GSK1059615 |
958852-01-2 |
C18H11N3O2S |
|
GRANULAR BLUE 粒蓝相似物 |
2-<4-(4-Amidinophenoxy)phenyl>indol-6-carboxamidin-dihydrochlorid |
55453-00-4 |
C22H19N5O*2ClH |
|
GR 127935盐酸盐 |
N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-carboxamide |
148672-13-3 |
C29H31N5O3 |
|
GPR109A受体激动剂(MK-0354) |
MK-0354 |
851776-28-8 |
C7H8N6 |
|
GNF179代谢物 |
2-(4-Fluorophenyl)-8,8-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine |
1310455-86-7 |
C14H16FN3 |
|
GNE-495游离态 |
8-amino-N-(1-(cyclopropanecarbonyl)azetidin-3-yl)-2-(3-fluorophenyl)-1,7-naphthyridine-5-carboxamide |
1449277-10-4 |
C22H20FN5O2 |
|
GNE-477抑制剂 |
GNE-477 |
1032754-81-6 |
C21H28N8O3S2 |
|
GNE-0877抑制剂 |
2-methyl-2-(3-methyl-4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)propanenitrile |
1374828-69-9 |
C14H16F3N7 |
|
GM1-五糖 |
LS-tetrasaccharide a |
52659-37-7 |
C37H62N2O29 |
|
GLYX13抑制剂 |
Glyx-13 |
117928-94-6 |
C18H31N5O6 |
|
GLPG0187,一种广谱的INTEGRIN受体拮抗剂,具有抗肿瘤活性 |
L-Alanine, 3-((2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl)-4-pyrimidinyl)amino)-N-((4-methoxyphenyl)sulfonyl) |
1320346-97-1 |
C29H37N7O5S |
|
GLPG-0634 中间体 |
N-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide |
1142943-96-1 |
C10H9BrN4O |
|
GJ103游离 |
2-((4-(3-methoxyphenyl)-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid |
1459687-89-8 |
C16H14N4O3S |
|
GJ-103钠盐 |
sodium 2-((4-(3-methoxyphenyl)-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)thio)acetate |
1459687-96-7 |
C16H13N4O3S*Na |
|
GENZ-644282抑制剂 |
2,3-dimethoxy-12-(2-(methylamino)ethyl)[1,3]dioxolo[4',5':4,5]-benzo[1,2-h]benzo[c][1,6]naphthyridin-13(12H)-one |
529488-28-6 |
C22H21N3O5 |
|
GDC-0349; N-Ethyl-N'-[4-[5,6,7,8-四氢-4-[(3S)-3-甲基-4-吗啉基]-7-(3-氧杂环丁基)吡啶并[3,4-d]嘧啶-2-基]苯基]脲 |
(S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea |
1207360-89-1 |
C24H32N6O3 |
|
GD-6肽 |
7,8,9-Trihydroxy-7,8,9,10-tetrahydrobenzo(a)pyrene-10-sulfonate |
124443-16-9 |
C20H16O6S |
|
GC-R2醚化物 |
N,N'-bis(2,6-diisopropylphenyl)-1,6,7,12-tetraphenoxy perylene-3,4:9,10-tetracarboxylic acid diimide |
123174-58-3 |
C72H58N2O8 |
|
GAMMA-谷氨酸 |
7-γ-L-glutamyl-4-methylcoumarinylamide |
72669-53-5 |
C15H16N2O5 |
|
GALUNISERTIB中间体 |
4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carbonitrile |
924898-13-5 |
C22H17N5 |
|
G9A和PRC2抑制剂(BRD9539) |
2-benzamido-1-(3-phenylpropyl)-1H-1,3-benzodiazole-5-carboxylic acid |
1374601-41-8 |
C24H21N3O3 |
|
G2聚糖 |
G2 Glycan |
71496-53-2 |
C62H104N4O46 |
|
G-碘丁腈 |
4-iodobutyronitrile |
6727-73-7 |
C4H6IN |
|
G-418 硫酸盐 |
geneticin sulfate |
108321-42-2 |
C20H40N4O10*H2O4S |
|
-D-吡喃半乳糖基)-β4-硝基苯基2-乙酰氨基-2-脱氧-3-O-(β |
Gal beta(1-3)GalNAc-beta-pNP |
59837-15-9 |
C20H28N2O13 |
|
(谷胱甘肽-S-基)二氢吗啡酮 |
(Glutathion-S-yl)dihydromorphinone |
119995-15-2 |
C27H34N4O9S |
|
(苯乙炔基)金 |
gold(I) phenylacetylide |
34679-27-1 |
C8H5Au |
|
(甲氧基甲基)环氧乙烷 |
glycidyl methyl ether |
930-37-0 |
C4H8O2 |
|
(甲基乙烯基醚/马来酸)半酯共聚物 |
Gantrez ES 425 |
25119-68-0 |
C11H18O5 |
|
(氨基亚胺甲基)硒基脲 |
guanylselenourea |
68516-47-2 |
C2H6N4Se |
|
(二甲基氨基亚甲基氨基亚甲基)二甲基氯化铵 |
Gold's reagent |
20353-93-9 |
C6H14N3*Cl |
|
(二氨基亚甲基氨基)膦酸 |
guanidine-N-phosphoric acid |
3019-36-1 |
CH6N3O3P |
|
(±)-甲氧基维拉帕米盐酸盐 |
gallopamil |
16662-47-8 |
C28H40N2O5 |
|
(±)-二氢-5-辛基-2(3H)-呋喃酮 |
gamma-dodecalactone |
2305-05-7 |
C12H22O2 |
|
(~73~Ga)镓 |
Gallium-73 |
15034-51-2 |
Ga |
|
(~72~Ga)镓 |
Gallium-72 |
13982-22-4 |
Ga |
|